Triple-negative breast cancer (TNBC), defined by the lack of expression of estrogen, progesterone, and epidermal growth factor receptor/human epidermal growth factor receptor 2 (ERBB2/HER2) receptors [1], represents 15% to 20% of all breast cancer cases [2] and occurs in young premenopausal women with a higher frequency [3]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.